Advanced Cell Technology Obtains FDA Approval to Treat Dry AMD with Embryonic Stem Cells

January 6, 2011

Advanced Cell Technology Inc., announced that it  had received approval from the FDA to commence its clinical trial using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat the dry form of age-related macular degeneration. ACT is now permitted to initiate a Phase I/II multicenter clinical trial to treat patients with dry AMD, the most common form of macular degeneration in the world.

“ACT is now the first company to receive FDA clearance for two hESC trials, and is now a true translational leader in the field of regenerative medicine,” said Gary Rabin, Interim Chairman and CEO of ACT. “It marks a major step forward, not just within the stem cell sector, but, potentially for modern healthcare techniques. We plan to proceed into the clinic with both of our hESC-based programs as quickly as possible.” (For both dry AMD and for treating Stargardt’s Disease, approval for which was obtained in November 2010.)

For the rest of the story see this link.




Jump down to form below to submit your own comments

2 Responses to “Advanced Cell Technology Obtains FDA Approval to Treat Dry AMD with Embryonic Stem Cells”

  • ari weitzner

    please refer to our stem cell section.
    if her disease started at age 18, its not age related macular degeneration, but some other variety. anyway, i am sorry but there is no stem cell or other treatment at this time- hopefully in the future.

  • Gary Cashman

    My fiancee has Age Related Macular Degeneration. She was diagnosed at the age of 18 and is now 49 yrs. old. Her vision is all but gone. Thank God some light is getting through, however it’s of very little use. Is there any new research that looks promising in a treatment to help restore any vision? Perhaps some Stem Cell research? Time is of the essence for her as well as many others. I still hold onto the hope for a miracle.